Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Jasper Therapeutics Inc (NASDAQ: JSPR) closed at $5.87 down -12.26% from its previous closing price of $6.69. In other words, the price has decreased by -$12.26 from its previous closing price. On the day, 1.3 million shares were traded. JSPR stock price reached its highest trading level at $6.725 during the session, while it also had its lowest trading level at $5.85.
Ratios:
For a deeper understanding of Jasper Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.61 and its Current Ratio is at 7.61. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on December 06, 2024, initiated with a Outperform rating and assigned the stock a target price of $63.
On September 09, 2024, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $70.
On July 08, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $90.BTIG Research initiated its Buy rating on July 08, 2024, with a $90 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 12 ’24 when Mahal Jeetinder Singh sold 900 shares for $22.11 per share. The transaction valued at 19,899 led to the insider holds 25,009 shares of the business.
Jeetinder Singh Mahal bought 900 shares of JSPR for $20,223 on Dec 12 ’24. On Sep 12 ’24, another insider, Mahal Jeetinder Singh, who serves as the Chief Operating Officer of the company, sold 900 shares for $21.23 each. As a result, the insider received 19,104 and left with 25,009 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JSPR now has a Market Capitalization of 88058216 and an Enterprise Value of -2375058.
Stock Price History:
The Beta on a monthly basis for JSPR is 2.26, which has changed by -0.37124062 over the last 52 weeks, in comparison to a change of 0.23147523 over the same period for the S&P500. Over the past 52 weeks, JSPR has reached a high of $31.01, while it has fallen to a 52-week low of $6.30. The 50-Day Moving Average of the stock is -71.67%, while the 200-Day Moving Average is calculated to be -72.39%.
Shares Statistics:
For the past three months, JSPR has traded an average of 440.10K shares per day and 1286400 over the past ten days. A total of 15.00M shares are outstanding, with a floating share count of 11.24M. Insiders hold about 25.11% of the company’s shares, while institutions hold 76.00% stake in the company. Shares short for JSPR as of 1735603200 were 2317294 with a Short Ratio of 5.27, compared to 1732838400 on 2055404. Therefore, it implies a Short% of Shares Outstanding of 2317294 and a Short% of Float of 15.65.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Jasper Therapeutics Inc (JSPR) in the stock market.The consensus estimate for the next quarter is -$1.35, with high estimates of -$1.02 and low estimates of -$1.48.
Analysts are recommending an EPS of between -$4.24 and -$4.55 for the fiscal current year, implying an average EPS of -$4.39. EPS for the following year is -$5.01, with 7.0 analysts recommending between -$3.65 and -$6.83.
